Gilde Healthcare raises a €100 million lower mid-market healthcare services fund - Gilde Healthcare

Gilde Healthcare raises a €100 million lower mid-market healthcare services fund

21 januari 2015

More capital available for healthcare service providers in the Benelux and Germany

Utrecht, The Netherlands – Gilde Healthcare, the private equity firm dedicated to the healthcare sector, today announces the first and final close of its €100 million Healthcare Services fund, Gilde Healthcare Services II. The new fund will support the growth of healthcare service companies in the Benelux and Germany.

The launch of the new fund comes at a time of healthcare reforms and market developments which leads to increased private entrepreneurship. Healthcare companies increasingly rely on private capital to finance their growth plans as government budgets are tightened and banks have less funds available to finance growth. The new Healthcare Services fund targets specialist clinics, elderly care, primary care, mental health, outsourcing services, medical product suppliers and other healthcare service providers. The fund has a differentiating investment strategy with a focus on companies that aim to provide better care at lower cost.

Jasper van Gorp, Managing Partner for Gilde Healthcare Services:

“We are delighted with the fundraising of our second healthcare services fund and in particular to have the backing of a strong base of blue chip investors. We now have the capital available to support more private healthcare companies. We focus on proven business models and work closely with management teams to further expand these businesses. We are proud to play an active role in improving the quality of healthcare services.“

In the past few years Gilde Healthcare Services has built a portfolio of fast growing companies. For example, the fund supported back pain specialist Fysius in their expansion from 13 to 26 branches, creating nationwide coverage and making specialized, yet affordable care available for patients with back pain. Gilde Healthcare Services also led the spinout of Viroclinics Biosciences from the Erasmus Medical Center. The fund provides hands-on support and capital for their international growth plan. Viroclinics is active in the field of virology diagnostic and contract research services to the pharmaceutical industry. The company has become the market leader in influenza and other infectious diseases, serving nearly all major pharmaceutical companies.

Currently, Gilde Healthcare Services is working on a number of new investment opportunities based on the proven strategy of investing in lower mid-market healthcare services companies with €7.5 million to €75 million in revenues. As per 1 January 2015, Matteo Racca was hired to strengthen the team as investment manager. Matteo has a background in strategy consulting and private equity.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, United States) is a private equity investor focused on fast growing healthcare businesses. It manages €550 million ($650 million) across five specialized funds. The Gilde Healthcare Services funds I and II focus on healthcare service providers, such as specialist clinics, elderly care, primary care, mental health, outsourcing services, medical product suppliers and other healthcare service providers in the Benelux and Germany. The Gilde Healthcare I, II and III Technology funds target companies developing medicines, medical devices and home & digital health solutions in Europe
and the US. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Note to the editor, not for publication:

Contacts at Gilde Healthcare

Jasper van Gorp
Managing Partner

Pieter van der Meer
Managing Partner

+31(0)302192533

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
30 oktober 2024

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant...
30 oktober 2024

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova...
9 oktober 2024